Epigenetic signatures and vascular risk in type 2 diabetes: A clinical perspective

Francesco Paneni, Sarah Costantino, Massimo Volpe, Thomas Felix Lüscher, Francesco Cosentino

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

Risk of diabetic complications continues to escalate overtime despite a multifactorial intervention with glucose-lowering drugs, anti-hypertensive agents and statins. In this perspective, a mechanisms-based therapeutic approach to vascular disease in diabetes represents a major challenge. Epigenetic signatures are emerging as important determinants of vascular disease in this setting. Methylation and acetylation of DNA and histones is a reversible process leading to dysregulation of oxidant and inflammatory genes such as mitochondrial adaptor p66Shc and transcription factor NF-kB p65. Epigenetic modifications associated with diabetes may contribute to the early identification of high risk individuals. Ongoing epigenomic analyses will be instrumental in identifying the epigenetic variations that are specifically associated with cardiovascular disease in patients with diabetes. Here, we describe a complex scenario of epigenetic changes and their putative link with diabetic vascular disease. Pharmacological reprogramming of diabetes-induced epigenetic signatures may be a promising option to dampen oxidative stress and inflammation, and thus prevent cardiovascular complications in this setting.

Original languageEnglish
Pages (from-to)191-197
Number of pages7
JournalAtherosclerosis
Volume230
Issue number2
DOIs
Publication statusPublished - Oct 2013

Fingerprint

Epigenomics
Type 2 Diabetes Mellitus
Blood Vessels
Vascular Diseases
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Diabetic Angiopathies
NF-kappa B
DNA Methylation
Diabetes Complications
Acetylation
Oxidants
Histones
Antihypertensive Agents
Oxidative Stress
Cardiovascular Diseases
Pharmacology
Inflammation
Glucose
Pharmaceutical Preparations
Genes

Keywords

  • Diabetes
  • Epigenetic changes
  • Oxidative stress
  • Vascular risk

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Epigenetic signatures and vascular risk in type 2 diabetes : A clinical perspective. / Paneni, Francesco; Costantino, Sarah; Volpe, Massimo; Lüscher, Thomas Felix; Cosentino, Francesco.

In: Atherosclerosis, Vol. 230, No. 2, 10.2013, p. 191-197.

Research output: Contribution to journalArticle

Paneni, Francesco ; Costantino, Sarah ; Volpe, Massimo ; Lüscher, Thomas Felix ; Cosentino, Francesco. / Epigenetic signatures and vascular risk in type 2 diabetes : A clinical perspective. In: Atherosclerosis. 2013 ; Vol. 230, No. 2. pp. 191-197.
@article{c4f0be93a9bd494eaa76e03a91ae023b,
title = "Epigenetic signatures and vascular risk in type 2 diabetes: A clinical perspective",
abstract = "Risk of diabetic complications continues to escalate overtime despite a multifactorial intervention with glucose-lowering drugs, anti-hypertensive agents and statins. In this perspective, a mechanisms-based therapeutic approach to vascular disease in diabetes represents a major challenge. Epigenetic signatures are emerging as important determinants of vascular disease in this setting. Methylation and acetylation of DNA and histones is a reversible process leading to dysregulation of oxidant and inflammatory genes such as mitochondrial adaptor p66Shc and transcription factor NF-kB p65. Epigenetic modifications associated with diabetes may contribute to the early identification of high risk individuals. Ongoing epigenomic analyses will be instrumental in identifying the epigenetic variations that are specifically associated with cardiovascular disease in patients with diabetes. Here, we describe a complex scenario of epigenetic changes and their putative link with diabetic vascular disease. Pharmacological reprogramming of diabetes-induced epigenetic signatures may be a promising option to dampen oxidative stress and inflammation, and thus prevent cardiovascular complications in this setting.",
keywords = "Diabetes, Epigenetic changes, Oxidative stress, Vascular risk",
author = "Francesco Paneni and Sarah Costantino and Massimo Volpe and L{\"u}scher, {Thomas Felix} and Francesco Cosentino",
year = "2013",
month = "10",
doi = "10.1016/j.atherosclerosis.2013.07.003",
language = "English",
volume = "230",
pages = "191--197",
journal = "Atherosclerosis",
issn = "0021-9150",
publisher = "Elsevier Ireland Ltd",
number = "2",

}

TY - JOUR

T1 - Epigenetic signatures and vascular risk in type 2 diabetes

T2 - A clinical perspective

AU - Paneni, Francesco

AU - Costantino, Sarah

AU - Volpe, Massimo

AU - Lüscher, Thomas Felix

AU - Cosentino, Francesco

PY - 2013/10

Y1 - 2013/10

N2 - Risk of diabetic complications continues to escalate overtime despite a multifactorial intervention with glucose-lowering drugs, anti-hypertensive agents and statins. In this perspective, a mechanisms-based therapeutic approach to vascular disease in diabetes represents a major challenge. Epigenetic signatures are emerging as important determinants of vascular disease in this setting. Methylation and acetylation of DNA and histones is a reversible process leading to dysregulation of oxidant and inflammatory genes such as mitochondrial adaptor p66Shc and transcription factor NF-kB p65. Epigenetic modifications associated with diabetes may contribute to the early identification of high risk individuals. Ongoing epigenomic analyses will be instrumental in identifying the epigenetic variations that are specifically associated with cardiovascular disease in patients with diabetes. Here, we describe a complex scenario of epigenetic changes and their putative link with diabetic vascular disease. Pharmacological reprogramming of diabetes-induced epigenetic signatures may be a promising option to dampen oxidative stress and inflammation, and thus prevent cardiovascular complications in this setting.

AB - Risk of diabetic complications continues to escalate overtime despite a multifactorial intervention with glucose-lowering drugs, anti-hypertensive agents and statins. In this perspective, a mechanisms-based therapeutic approach to vascular disease in diabetes represents a major challenge. Epigenetic signatures are emerging as important determinants of vascular disease in this setting. Methylation and acetylation of DNA and histones is a reversible process leading to dysregulation of oxidant and inflammatory genes such as mitochondrial adaptor p66Shc and transcription factor NF-kB p65. Epigenetic modifications associated with diabetes may contribute to the early identification of high risk individuals. Ongoing epigenomic analyses will be instrumental in identifying the epigenetic variations that are specifically associated with cardiovascular disease in patients with diabetes. Here, we describe a complex scenario of epigenetic changes and their putative link with diabetic vascular disease. Pharmacological reprogramming of diabetes-induced epigenetic signatures may be a promising option to dampen oxidative stress and inflammation, and thus prevent cardiovascular complications in this setting.

KW - Diabetes

KW - Epigenetic changes

KW - Oxidative stress

KW - Vascular risk

UR - http://www.scopus.com/inward/record.url?scp=84884562282&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84884562282&partnerID=8YFLogxK

U2 - 10.1016/j.atherosclerosis.2013.07.003

DO - 10.1016/j.atherosclerosis.2013.07.003

M3 - Article

C2 - 24075743

AN - SCOPUS:84884562282

VL - 230

SP - 191

EP - 197

JO - Atherosclerosis

JF - Atherosclerosis

SN - 0021-9150

IS - 2

ER -